Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Allodepleted T-cell ImmunotheRapeutics

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Nanofluidic drug‐eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer
ABSTRACT Conventional systemic immunotherapy administration often results in insufficient anti‐tumor immune response and adverse… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 6
Review
2018
Review
2018
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
Passive immunotherapy has emerged as a very promising approach for the treatment of Alzheimer’s disease and other… Expand
  • table 1
  • table 1
  • figure 1
2015
2015
Specific in vitro binding of a new (99m)Tc-radiolabeled derivative of the C-terminal decapeptide of prothymosin alpha on human neutrophils.
Prothymosin alpha (ProTα) is a conserved mammalian polypeptide with intracellular functions associated with cell proliferation… Expand
2011
2011
Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth
Monoclonal antibodies (mAbs) to HER2 are currently used to treat breast cancer, but low clinical efficacy, along with primary and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2007
2007
Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein.
Medical countermeasures to prevent or treat smallpox are needed due to the potential use of poxviruses as biological weapons… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
2005
2005
Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications.
United Biomedical, Inc. (UBI) has developed a set of core technologies for the discovery and production of synthetic peptide… Expand
  • figure 1
  • figure 2
  • table 2
  • figure 3
  • table 3
Highly Cited
1997
Highly Cited
1997
Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes
Elevated levels of the p53 protein occur in ∼50% of human malignancies, which makes it an excellent target for a broad-spectrum T… Expand
  • figure 1
  • figure 3
  • figure 2
  • table 1
1997
1997
Tolerance to p 53 by A 2 . 1-restricted Cytotoxic T Lymphocytes
Elevated levels of the p53 protein occur in , 50% of human malignancies, which makes it an excellent target for a broad-spectrum… Expand
  • figure 1
  • figure 3
  • figure 2
  • table 1
1990
1990
[The effect of Echinacea purpurea Moench on phagocytosis in granulocytes measured by chemiluminescence].
Chemiluminescence was used as an indicator for phagocytic activity of granulocytes induced by zymosan in whole blood. Luminol was… Expand
1983
1983
The immunologic and immunotherapeutic sequelae of intraperitoneal BCG. II: Serial changes in spleen weight, morphology, cell populations and in vitro mitogen responses.
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE